The FDA cleared Wave Neuroscience's MeRT system as an adjunct treatment for PTSD. MeRT uses a patient's own EEG-derived brain activity to tailor the delivery of transcranial magnetic stimulation, an individualized approach to dosing that distinguishes it from fixed-protocol TMS. Clearance was supported by a double-blind, randomized, multi-site trial run with Texas A&M Health and builds on the company's 2024 Breakthrough Device designation. It is the latest in a recent run of PTSD neuromodulation clearances, following GrayMatters Health's neurofeedback-based Prism and Neurovalens' vestibular-stimulation device, a sign of a more active regulatory path for brain-based PTSD treatment.